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Abstract
Background—Several studies have demonstrated better outcomes for carotid endarterectomy
with high-volume hospitals and providers. However, only a few studies have reported on the
impact of operator specialty/volume on the perioperative outcome of carotid artery stenting (CAS).
This study will analyze the correlation of CAS outcomes and provider specialty and volume.
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Methods—Prospectively collected data of CAS procedures done at our institution during a 10year period were analyzed. Major adverse events (MAEs; 30-day stroke, myocardial infarction,
and death) were compared according to provider specialty (vascular surgeons [VSs], interventional
cardiologists [ICs], interventional radiologists [IRs], interventional vascular medicine [IVM]), and
volume (≥5 CAS/year vs. <5 CAS/year).
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Results—Four hundred fourteen CAS procedures (44% for symptomatic indications) were
analyzed. Demographics/clinical characteristics were somewhat similar between specialties. MAE
rates were not significantly different between various specialties: 3.1% for IC, 6.3% for VS, 7.1%
for IR, 6.7% for IVM (P = 0.3121; 6.3% for VS and 3.8% for others combined, P = 0.2469). When
physicians with <5 CAS/year were excluded: the MAE rates were 3.1% for IC, 4.7% for VS, and
6.7% for IVM (P = 0.5633). When VS alone were compared with others, and physicians with <5
CAS/year were excluded, the MAE rates were 4.7% for VS vs. 3.6% for non-VS (P = 0.5958).
The MAE rates for low-volume providers, regardless of their specialty, were 9.5% vs. 4% for highvolume providers (P = 0.1002). Logistic regression analysis showed that the odds ratio of MAE
was 0.4 (0.15–1.1, P = 0.0674) for high-volume providers, while the odds ratio for VS was 1.3
(0.45–3.954, P = 0.5969).
Conclusions—Perioperative MAE rates for CAS were similar between various providers,
regardless of specialties, particularly for vascular surgeons with similar volume to nonvascular
surgeons. Low-volume providers had higher MAE rates.
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INTRODUCTION
It has been suggested that carotid artery stenting (CAS) is a reasonable alternative to carotid
endarterectomy (CEA) in treating significant carotid artery stenosis in well-experienced
high-volume centers.1,2 These data also suggest that future prospective trials comparing
CEA and CAS outcomes should only include centers that are experienced in both treatment
modalities.2
Multiple studies have documented that high-volume providers are a predictor of better
outcomes with CEA.3–6 Therefore, it would be reasonable to expect that if the volume of
cases performed by surgeons impacts the outcome of CEA, then the same should be
expected with CAS.

Author Manuscript

There has also been an ongoing debate as to whether operator specialty impacts the outcome
of CAS. This may directly affect credentialing decisions when discussed on a local or
national level.
Only a few studies have reported on the impact of operator specialty/volume on the
perioperative outcome of CAS.2,4,7–9 Our present study will analyze the correlation of CAS
outcome and provider specialty and volume.
Patient Population and Methods
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This is a retrospective analysis of prospectively collected data of CAS procedures done at
our institution during a 10-year period. Informed consent was not necessary as all data were
anonymous and no personal patient information was identified. This study was approved by
the Institutional Review Board of West Virginia University/Charleston Area Medical Center.
It included all patients enrolled in several carotid clinical trials, including Carotid RX
ACCULINK/RX ACCUNET Post-Approval Trial to Uncover Unanticipated or Rare Events
(CAPTURE; Abbott Vascular, Santa Clara, CA), MAVErIC (Medtronic AVE SelfExpanding CaRotid Stent System with distal protection In the treatment of Carotid stenosis,
Medtronic, Minneapolis, MN) 1, 2, and 3, Parodi (Parodi Anti-Emboli System as an
adjuvant cerebral protection device during Carotid Stent-supported angioplasty with the
Boston Scientific Carotid Wallstent Monorail Endoprosthesis, Boston Scientific, Natick,
MA), SHELTER (Stenting of High Risk Patients: Extracranial Lesion Trial with Emboli
Removal, Boston Scientific, Natick, MA), EXACT (Emboshield and Xact Post Approval
Carotid Stent Trial by Abbott, Abbott Park, IL), VIVA (ViVEXX Carotid Revascularization
Trial), Carotid Stenting for High Surgical-Risk Patients (CHOICE; Abbott, Abbott Park, IL),
CANOPY (Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid
Endarterectomy by Abbott, Natick, MA), and Carotid Revascularization Endarterectomy
versus Stenting Trial (CREST), by National Institute of Neurologic Disorders and Stroke.
Indications for CAS were symptomatic patients (transient ischemic attacks [TIAs]/stroke)
with ≥50% ipsilateral carotid stenosis by conventional angiography or ≥70% stenosis by
duplex ultrasound, computed topography angiography, or magnetic resonance angiography
and asymptomatic patients with ≥80% carotid stenosis based on duplex ultrasound and/or
computed topography angiography/magnetic resonance angiography. All patients were
treated with aspirin (325 mg) and clopidogrel (75 mg), 48–72 hr prior to the procedure,
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which was continued for 30 days after the procedure for clopidogrel and indefinitely for
aspirin. All CAS procedures were done according to their trial protocol and using cerebral
protection devices.
Provider Specialty and Volume
All providers had full training in endovascular therapy and full privileges in carotid stenting
at our institution, which included a minimum of 1 year of an interventional vascular
fellowship for interventional cardiologists (ICs) and interventional radiologists (IRs), and 2
years of an interventional vascular fellowship for vascular medicine and completion of ≥25
carotid stentings (for all providers) during their training before being granted CAS
privileges. All vascular surgeons (VSs) were board certified (Vascular Surgery Board/
American Board of Surgery) and also completed ≥25 CAS procedures. Accordingly,
providers were classified into: VSs, ICs, IRs, and interventional vascular medicine (IVM).
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The annual provider volume for CAS was calculated using the number of CAS procedures
done by each provider during the study period, divided by the number of years that the
provider performed CAS procedures. Provider volume was classified as: low volume (<5
CAS procedures per year) versus median/high volume (≥5 CAS procedures per year).10,11
Primary Outcome and End Points
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The primary end point of the study was the composite outcome of major adverse events
(MAEs), which included 30-day perioperative stroke, myocardial infarction (MI), and/or
death. Periprocedural neurological evaluations were performed before and immediately after
CAS and at 24–48 hr postprocedure. All patients, who were part of carotid clinical trials,
had cardiac isoenzyme levels and electrocardiograms before the procedure and again at 24–
48 hr postoperatively. These tests were also done on all patients who developed chest pain
after the CAS procedure. MI was defined as electrocardiogram evidence of ischemia or
biomarker elevation with chest pain.

STATISTICAL METHODS
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A statistical analysis was performed using SAS 9.2 software (Cary, NC). A univariate
analysis was performed on patient demographics and clinical characteristics. Continuous
data were reported as means with a standard deviation. The 30-day MAE rates were
compared between various providers, according to specialty and annual CAS volume. A
logistic regression analysis was also used to examine the correlation between provider
specialty and volume and the composite end point (MAE), adjusting for various patient
demographics/clinical characteristics and indications for CAS. The threshold for
significance was 0.05.

RESULTS
Four hundred fourteen CAS procedures were analyzed. Fifty-six percent were done for
asymptomatic stenoses and 44% for TIA and/or stroke symptoms. Tables I and II summarize
the demographics and clinical characteristics according to provider specialty (VS versus
non-VS [other providers]) and volume. There were no statistically significant differences
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among various clinical characteristics and provider specialties, except for CAS indications,
where 49% of CAS performed by VS were for asymptomatic indications versus 61% for
non-VSs (P = 0.0146). Similar observations were noted for low-volume providers versus
high-volume providers (40% vs. 59%, P = 0.0052, for asymptomatic indications).
Clinical Outcome and Provider Specialty and Volume
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Table III summarizes the MAE rates (30-day stroke, MI, and death) according to provider.
As noted, there were no significant differences in MAE rates between various specialties (P
= 0.3121) and when all VSs were compared with all other providers (6.3% vs. 3.8%; P =
0.2469). The MAE rates were also similar between various specialties when only highvolume providers were analyzed (excluding providers with <5 CAS per year; P = 0.5633).
High-volume VS also had similar MAE rates to other high-volume providers (4.7% vs.
3.6%, P = 0.5958). In addition, there were no significant differences in MAE rates between
VSs and other providers, specifically when high-volume VSs were compared with highvolume other providers, regardless of the symptomatic status: for symptomatic patients
(9.5% vs. 3.2%, P = 0.1589) and for asymptomatic patients (0% vs. 3.5%, P = 0.1728) Table
IV summarizes the MAE rates according to provider volume only. As noted, there was a
tendency toward higher MAE rates in patients with low-volume providers versus highvolume providers (9.5% vs. 4%, P = 0.1002). To be noted, this could have been statistically
significant if the sample size was larger, that is, type 2 statistical error is likely to be the
cause of the nonsignificant P value.
Logistic Regression Analysis
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Table V summarizes the odds ratio of MAE rates according to provider volume/specialty and
other comorbidities. As noted, high-volume providers had an odds ratio of 0.4, compared
with low-volume providers (P = 0.0674). Meanwhile, VS (versus other providers) had an
odds ratio of 1.3 (P = 0.5969).

DISCUSSION
It has been well documented in multiple studies that high-volume providers are a predictor
of better outcomes with CEA.3–6 In a study by our group evaluating outcomes on 953 CEAs
performed over a 2-year period at a single high-volume center; high-volume surgeons (<30
CEAs/year) had a significantly decreased perioperative stroke/death rate when compared
with low/medium-volume surgeons (<30 CEAs/year; 1.3% vs. 4.15%).3 It would be
reasonable to expect that if the volume of cases performed by surgeons impacts the outcome
of CEA, then the same should be expected with CAS.

Author Manuscript

The preferred mode of treatment of carotid artery atherosclerotic stenosis has been a topic of
debate. It is widely accepted that patients with carotid artery stenosis, who are at high risk
for CEA, should be considered for CAS. However, in normal risk patients, the most
appropriate choice of treatment is a controversial topic that is often discussed, with the
results of the CREST dissected and debated by experts in all specialties that have a role in
treatment.12 Despite the controversy regarding the preferred mode of treatment, the number
of CAS procedures performed in the United States has continued to increase with a
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concurrent decrease in the annual number of CEA procedures that are performed.13 There
has been an ongoing debate as to whether operator specialty and experience affect outcomes
when CAS is performed. This is a very important topic since it directly affects credentialing
decisions at both a national level and local level. Also, this raises the question as to whether
low-volume operators should continue to perform CAS or should only a few selected highvolume operators perform CAS at institutions that can provide the necessary volume to
maintain skilled and competent operators.

Author Manuscript

Our study wasdesignedto add insightinto this difficult dilemma and to address the effect of
both operator experience and specialty on CAS outcomes. Our study was unique in that it
was performed at a single high-volume center with multiple operator specialties and
different operator experience levels. It demonstrated that operator specialty did not
determine perioperative MAEs (death, stroke, and MI) but that low-volume providers did
have higher MAE rates.

Author Manuscript
Author Manuscript

Several prospective multicenter studies have evaluated operator experience to determine if it
predicts outcomes with CAS, with varying results.10–17 The Carotid ACCULINK/
ACCUNET Post Approval Trial to Uncover Rare Events (CAPTURE 2) Study (5,297
patients) and CHOICE (Evaluating Outcomes Through the Collection of Clinical Evidence)
Study (5,841 patients) both demonstrated that physician experience impacted CAS
outcome.15,17; conversely, the Carotid Stenting Boston Scientific Surveillance Program
(CABANA) Study (1,025 patients) and CAPTURE Study (3,500 patients) did not find that
operator experience impacted outcomes.14,16 It is important to note that in both the
CAPTURE and CABANA studies, more emphasis was placed on operator experience with
the investigational device, rather than carotid stenting volume in general, and this may have
impacted the analysis.14,16 Also, the CAPTURE Study used the number of CAS procedures
performed before the trial, instead of the annual volume or number of patients enrolled in the
study by the operator, to define experience. The CABANA Study did use procedures/month
as part of the metric for operator experience, but as stated previously, used operator
experience with the investigational device.16 Interestingly, the CHOICE Study found that an
increased time interval between the first CAS and subsequent CAS procedures was the only
independent predictor of 30-day death, stroke, and MI after CAS.15 Meanwhile, the
CAPTURE 2 study found that there was an inverse relationship between adverse events and
operator volume.17 The results from these prospective multicenter studies are in general
agreement with our findings. Our study demonstrated that low-volume providers had higher
MAE rates than high-volume providers (9.5% vs. 4%, respectively). Although not
statistically significant, there was a definite trend toward significance (P = 0.0674) with
logistic regression analysis. We approached the experience of the operator by using annual
volume as a measure of experience, rather than assessing the total volume of CAS
procedures done by the operator in the past. Both CAPTURE 2 and CHOICE studies found
that the operator’s current CAS volume predicted outcome, which is in agreement with our
findings.15–17
Although our literature search did not identify a study similar to ours (where CAS outcomes
were evaluated to address if operator experience impacted outcomes at a single center with
multiple specialties); other studies have evaluated databases to address this issue. One such
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study by Modrall et al.10 utilized the Nationwide Inpatient Sample(NIS) database to evaluate
if CAS volume, endovascular aneurysm repair (EVAR) volume, thoracic endovascular aortic
aneurysm repair (TEVAR) volume, and percutaneous coronary intervention (PCI) volume by
the operator, affected CAS outcome defined by the in-hospital stroke/death rate. CAS
volume, EVAR/TEVAR volume, and PCI volume were defined by the number of procedures
per year. CAS volume was defined as low, medium, and high volume (<5, 5 to <15, and >15
procedures per year, respectively). The authors demonstrated that the risk of stroke/death
with CAS decreased with increasing CAS volume, as well as with increasing EVAR/TEVAR
volume by the operator.10 Conversely, increasing PCI volume was actually associated with
an increasing likelihood of stroke/death after CAS. Other studies have also utilized regional
and national databases to evaluate if annual CAS volume impacts outcome and, not
surprisingly, have demonstrated decreased complications when CAS is performed by highvolume operators.18–20 However, a study of 4,001 CAS procedures by Steppacher et al.7 did
not demonstrate a difference in the in-patient death/ stroke rate based on operator volume,
but their categories for physician volume were different from ours, and this may have
affected the results. Their categories were separated into low (<9 cases/year), medium (9–23
cases/year), and high (>23 cases/ year), while our study considered operators with < 5 cases/
year as low volume.

Author Manuscript

One last important study that examined if operator volume impacted CAS outcomes was a
study by ‘‘The Carotid Stenting Trialists’’ Collaboration, which pooled data from 3
randomized trials, including the Endarterectomy Versus Angioplasty in patients with
Symptomatic Severe Carotid Stenosis trial, the Stent-Protected Angioplasty versus Carotid
Endarterectomy trial, and the International Carotid Stenting Study.11 In this study, 1,546
patients underwent CAS and both lifetime stenting experience excluding the carotid and
lifetime CAS experience did not impact the 30-day risk of stroke or death. However, the
annual in-trial CAS volume of the operator significantly impacted outcomes; low-volume
providers (mean ≤ 3.2 procedures/year) had a 30-day death/ stroke risk of 10.1% and
intermediate-volume providers (3.2–5.6 procedure/year) had a 30-day death/stroke risk of
8.4%, compared with high-volume providers (>5.6 procedures/year), who had a 30-day
death/stroke risk of 5.1%.

Author Manuscript

Our study found no difference in CAS outcomes between operators of different specialties.
We have a very diverse group of specialties performing CAS procedures at our institution,
including vascular surgery, interventional cardiology, IVM, and interventional radiology.
Our results demonstrated that physician specialty does not predict adverse outcomes with
CAS, which is in agreement with a majority of studies that have evaluated this intriguing
topic, given the diversity of training paradigms adopted by each specialty. However, some
studies have demonstrated differences. Probably the most well-known study that has
demonstrated a difference in outcomes based on operator specialty was the lead-in phase of
CREST, which found that vascular surgery had an increased death, stroke, and MI rate,
relative to ICs.8 It was also surprising that the years of experience or number of CAS
procedures submitted before the lead-in phase did not significantly affect outcomes.8
However, it is very important to realize that when the results of the randomized patients
enrolled in CREST were published, there was no difference in outcomes for CAS, based on
operator specialty.9,12
Ann Vasc Surg. Author manuscript; available in PMC 2018 October 01.
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Other prospective multicenter studies have likewise addressed this issue. The CAPTURE 2
study found that ICs tended to have a lower 30-day death/stroke rate than other specialties,
but the difference was not statistically significant.17 The CHOICE study separated the
specialties into surgery, radiology/neurology, and cardiology.15 This study demonstrated that
cardiologists had reduced embolic protection device dwell times (the time during which the
cerebral protection devices were deployed in place), compared with surgery and radiology/
neurology, but the 30-day death/stroke/MI rates did not differ between the 3 specialties.15
The CAPTURE study also found no difference in the 30-day death/stroke/MI rate, based on
specialty.14
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A few other studies have used regional and national databases to evaluate if operator
specialty affects CAS outcomes. Vogel et al.21 evaluated the State Inpatient Databases for
New Jersey and found that in 625 CAS cases, the stroke rate was not significantly different
between specialties (VSs, cardiolo-gists, and radiologists). Interestingly, however, VSs did
have a lower mean total hospital cost, compared with radiology and cardiology. Steppacher
et al.7 used the State In-patient Databases from New York and Florida and evaluated 4,001
CAS procedures. They demonstrated no difference in the in-patient mortality or stroke rates
between interventional cardiology, vascular surgery, and interventional radiology. Again,
VSs did have significantly lower total hospital charges than the non-VS group. Finally, Sgroi
et al.22 evaluated 20,663 CAS procedures from the NIS database. Operators were separated
into surgeons and interventionalists, and the study demonstrated that the 30-day stroke/MI/
death rates were not significantly different between the 2 groups.22 However, again it was
demonstrated that the interventionalists did have increased hospital charges, compared with
surgeons; and when interventionalists performed the procedure, the hospital stay was
longer.22 Our study did not evaluate hospital charges or length of stay between specialties,
but we may consider evaluating this in the future in our patient cohort.
Study Limitations

Author Manuscript

Our study does have some limitations. First, it was a single-center study and regional
variations in patient population and providers may not apply to the entire United States
population. Also, our provider volume results did not reach statistical significance, and this
may be related to an inadequate sample size, given the strong trend that was seen in our
results. We also used the composite end point of MAE (defined as the 30-day hospital
stroke, death, and/or MI). We did not perform an analysis on the end points of death, stroke,
and MI separately. An example of this is that the subgroup of IVM had 2 patients with a 30day mortality and met the MAE end point, but no patients in that specialty’s cohort had a
stroke within the 30-day postoperative period. Finally, this was a retrospective analysis of
prospectively collected data and reporting bias could lead to some error.

CONCLUSIONS
This study demonstrates that provider volume is an important predictor of outcome with
CAS. Providers who have a low annual volume of CAS procedures have higher rates of
MAEs. Conversely, provider specialty was not found to predict major adverse events. This
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demonstrates the need for provider annual volume to be considered in maintaining CAS
privileges in order to minimize the risk of adverse events.
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Demographic and clinical characteristics by provider specialty
Demographic/clinical characteristic
Mean age

Author Manuscript

a

Vascular surgeons (total = 176); no. (%)

Other providers (total = 238); no. (%)

P value

67.9 (range: 48–88)

69 (range: 40–88)

0.2709

Male gender

110 (63%)

143 (60%)

0.6181

Hypertension

155 (88%)

212 (89%)

0.7494

Diabetes

67 (38%)

113 (47%)

0.0562

Coronary artery disease

123 (70%)

182 (76%)

0.1326

Congestive heart failure

40 (23%)

60 (25%)

0.5596

Hypercholesterolemia

141 (80%)

169 (71%)

0.0347

Renal failure

31 (18%)

61 (26%)

0.0524

Smoking

105 (60%)

146 (61%)

0.7286

Indication–asymptomatica

86 (49%)

145 (61%)

0.0146

Indication–TIAa

79 (45%)

74 (31%)

0.004

Indication–strokea

14 (8%)

27 (11%)

0.2536

A few patients had multiple symptoms.
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Table II

Author Manuscript

Demographic and clinical characteristics and provider volume
Demographic/clinical characteristic
Mean age

Author Manuscript

a

Low volume (<5/year; total = 63); no.
(%)

Medium/high volume (≥5/year; total =
351); no. (%)

P value

66.9 (range: 43–83)

68.8 (range: 40–88)

0.153

Male gender

39 (62%)

214 (61%)

0.8884

Hypertension

57 (90%)

310 (88%)

0.6192

Diabetes

26 (41%)

154 (44%)

0.701

Coronary artery disease

44 (70%)

261 (74%)

0.4534

Congestive heart failure

14 (22%)

86 (25%)

0.6971

Hypercholesterolemia

49 (78%)

261 (74%)

0.5645

Renal failure

14 (22%)

78 (22%)

1

Smoking

38 (60%)

213 (61%)

0.9563

Indication—asymptomatica

25 (40%)

206 (59%)

0.0052

Indication—TIAa

30 (48%)

123 (35%)

0.0569

Indication—strokea

9 (14%)

32 (9%)

0.206

A few patients had multiple symptoms.
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Author Manuscript

Author Manuscript

Author Manuscript

Nonstroke–related deaths.

a

6/194 (3.1%)

High-volume vascular surgeons versus other high-volume providers

High-volume providers only/specialty

11/176 (6.3%)

Vascular surgeons no. (%)

11/176 (6.3%)

Vascular surgeons no. (%)

Interventional cardiologists no. (%)

6/194 (3.1%)

All providers

All vascular surgeons versus all other providers

Interventional cardiologists no.
(%)

Perioperative MAEs

6/127 (4.7%)

Vascular surgeons no. (%)

6/127 (4.7%)

Vascular surgeons no. (%)

1/14 (7.1%)

Interventional radiologists
no. (%)

Perioperative major adverse events (stroke/MI/death): provider specialty and volume

2/30 (6.7%)

14/351 (4%)

Total no. (%)

20/414 (4.8%)

8/224 (3.6%)

Other providers no. (%)

Interventional Vascular
medicine no. (%)

9/238 (3.8%)

Total no. (%)

20/414 (4.8%)

2/30 (6.7%)a
Other providers no. (%)

Total no. (%)

Interventional vascular
medicine no. (%)

Author Manuscript

Table III

0.5958

P value

0.5633

P value

0.2469

P value

0.3121

P value

AbuRahma et al.
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Table IV

Author Manuscript

Perioperative major adverse events (stroke/myocardial infarction/death): volume only
Low volume (<5/year);

High volume (≥5/year);

Perioperative MAE

no. (%)

no. (%)

P value

MAE rate

6/63 (9.5%)

14/351 (4%)

0.1002

Author Manuscript
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Table V

Author Manuscript

Logistic regression analysis: major adverse events

Author Manuscript

a

Demographic/clinical characteristic

MAE: odds ratio and 95% confidence interval

P value

Gender–male

1.2 (0.47–3.05)

0.7149

Hypertension

0.5 (0.16–1.53)

0.2202

Diabetes

1.6 (0.66–4.02)

0.2908

Coronary artery disease

1.1 (0.38–3.03)

0.89

Congestive heart failure

1.1 (0.37–2.96)

0.9279

Renal failure

1.2 (0.42–3.33)

0.7596

Indication–asymptomatic

0.4 (0.16–1.05)

0.0621

Volume(>5 per year)a

0.4 (0.15–1.07)

0.0674

Vascular surgeonb

1.3 (0.45–3.95)

0.5969

Age

1.0 (0.97–1.07)

0.4555

This odds ratio and 95% confidence interval is for ≥5 CAS procedures per year versus <5 CAS per year.

b

This odds ratio and 95% confidence interval is for vascular surgeons versus other providers.
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